Oric Pharmaceuticals Inc.宣布,已与英国癌症研究院(Cancer Research UK)签署协议,旨在将一款潜在的首创Cip2a靶向疗法推进至临床开发阶段。
Oric Pharmaceuticals Inc.宣布,已与英国癌症研究院(Cancer Research UK)签署协议,旨在将一款潜在的首创Cip2a靶向疗法推进至临床开发阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.